A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Official title

A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Overview

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

Detailed description

This is a Phase 1/2a, open-label, first-in-human study of T3011 given via intratumoral (IT) injection as a single agent and in combination with IV pembrolizumab in participants with advanced or metastatic solid tumors. The Phase 1 portion of the study is a single agent dose escalation which will use a 3+3 design to evaluate escalating doses of T3011. Total enrollment will depend on the toxicities and/or activity observed, with approximately 15 to 30 evaluable participants enrolled. Once the RP2D is established Phase 2a Part 1 will enroll approximately 10 participants with locally recurrent or metastatic melanoma (in Arm A) 23 to 53 participants with HNSCC in Arm B, 40 to 80 participants with sarcoma in Arm C and 10 participants with cSCC in Arm D. During Phase 2a Part 1 the safety, tolerability, and preliminary efficacy of T3011 as a single agent will be evaluated. Phase 2a Part 2 will enroll in parallel to Phase 2a Part 1 once the RP2D is established. The safety, tolerability, and preliminary efficacy of IT T3011 given in combination with IV pembrolizumab will be evaluated in 15 participants with histologically or pathologically confirmed metastatic NSCLC (Arm E). A rollover arm is also included in this study to allow participants who have documented progression on T3011 alone to receive T3011 in combination with pembrolizumab if considered eligible.

Interventions

• Biological T3011
  T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
• Combination product T3011 + pembrolizumab
  T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.

Primary outcome measures

• Safety and tolerability of escalating doses T3011 [Time frame: Up to 2 years from first dose of T3011]
• To determine the dose(s) of T3011 to be examined in Phase 2a [Time frame: Through the first two T3011 injections (approximately 28 days)]
• Safety and tolerability of T3011 dose(s) selected from Phase 1 in disease specific cohorts [Time frame: Up to 2 years from first dose of T3011]
• Characterize the safety and tolerability of T3011 in combination with pembrolizumab [Time frame: Up to 2 years from first dose of T3011]
• Characterize the safety and tolerability of T3011 in combination with pembrolizumab in participants who progress on T3011 alone [Time frame: Up to 2 years from first dose of T3011]

Secondary outcome measures (8)

• Overall response rate (ORR) [Time frame: Up to 2 years from first dose of T3011]
• Disease control rate (DCR) [Time frame: Up to 2 years from first dose of T3011]
• Duration of response (DOR) [Time frame: Up to 2 years from first dose of T3011]
• Durable response (DR) [Time frame: Up to 2 years from first dose of T3011]
• Progression-free survival (PFS) [Time frame: Up to 2 years from first dose of T3011]
• Overall Survival (OS) [Time frame: Up to 1 year after last dose of T3011]
• Presence of neutralizing antibodies of anti-PD-1 antibody for antidrug antibodies (ADAs) development [Time frame: Up to 2 years from first dose of T3011]
• Presence and frequency of T3011 in injection site swab, saliva, and urine [Time frame: Up to 2 years from first dose of T3011]

Eligibility criteria

Inclusion criteria

• Age 18 years or older.
• Disease progression after standard of care (SOC) therapy or in the opinion of
• The Investigator unlikely to benefit from SOC therapy. Inclusion Diagnosis Phase 1 - Histologically or pathologically confirmed locally recurrent or metastatic advanced malignancy.

Phase 2a Part 1 i. Arm A - locally recurrent or metastatic melanoma. Participants must have received no more than 3 prior regimens for advanced or metastatic disease.

ii. Arm B - locally recurrent or metastatic HNSCC. It must also meet the following criteria: 1) Disease progression to platinum-containing chemotherapy; 2) Failure to anti-PD-1/PDL1 blockade after receiving at least 2 doses alone or in combination.

iii. Arm C - Sarcoma. Participants must have received no more than three lines of prior anti-cancer therapies.

iv. Arm D - locally recurrent or metastatic cSCC. Participants must have received no more than 3 prior regimens for advanced or metastatic disease.

Phase 2a Part 2 i.v. Arm E - Histologically or pathologically confirmed NSCLC that is advanced or recurrent, without EGFR mutation or ALK rearrangement. Participants must have received at least one line but no more than three lines of prior anti-cancer therapies.

• Measurable disease per RECIST version 1.1.
• Must have at least 1 tumor lesion that is accessible for IT injection of T3011 in the opinion of the investigator.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• Life expectancy > 12 weeks.
• Demonstrate adequate organ function as defined by acceptable laboratory testing results.
• Women of child-bearing potential (WCBP) and men must agree to use adequate contraception prior to study entry, while on study treatment, and for six months after receiving last dose of T3011. WCBP must have a negative serum pregnancy test prior to W1D1.
• Last dose of previous anticancer therapy ≥ 21 days, radiotherapy > 21 days, or surgical intervention > 21 days prior to the first dose of T3011.
• Recovered from all prior anticancer therapy toxicities.
• Willingness to provide fresh tumor biopsy specimens as specified in the Schedule of Assessments.
• Capable of understanding and complying with protocol requirements.
• Signed and dated institutional review board/independent ethics committee-approved informed consent form before any protocol-directed screening procedures are performed.

Exclusion criteria

• Have only uninjectable tumors..
• Patients with injectable tumors impinging upon major airways or blood vessels.
• HNSCC only: Prior re-irradiation field containing carotid artery.
• Greater than 3 distant metastatic lymph node regions and/or metastatic lesions or the largest distant metastases with a diameter of more than 3 cm (non-sarcoma)/5 cm (sarcoma) unless the lesion is to be injected.
• Prior treatment with another OV (including T-VEC), tumor vaccines, cellular therapy or gene therapy.
• Prior intolerance to anti-PD-(L)1 monoclonal antibody or history of immunotherapy related non-infectious pneumonitis/interstitial lung disease.
• Prior treatment with anti-PD-(L)1 monoclonal antibody in combination with IL-12.
• Requires continued concurrent therapy with any drug active against HSV.
• Live vaccines, attenuated vaccines within 4 weeks prior to initiation of study treatment (participants vaccinated with inactivated vaccines can be enrolled.
• Primary or acquired immunodeficient states.
• Pregnant or lactating.
• Prior organ transplantation.
• Active hepatitis B virus, hepatitis C virus, and HIV infection or a positive serological test at Screening within 14 days of dosing with T3011.
• Active autoimmune disease or medical conditions requiring chronic steroid or immunosuppressive therapy within 4 weeks prior to first administration of study treatment.
• History of or current central nervous system metastases.
• History of seizure disorders within 6 months of Screening.
• Active oral or skin herpes lesion at Screening.
• Active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids.
• Congestive heart failure, active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina, or clinically significant cardiac arrhythmias.
• History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody.

18\. Active infection with SARS-CoV-2 virus. 21. Participants with moderate to large amount of pleural effusion, ascites or pericardial effusion who need drug or medical intervention.

22\. Other systemic conditions or organ abnormalities that, in the opinion of the investigator, may interfere with the conduct and/or interpretation of the current study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 6 centers

• Banner MD Anderson Cancer Center — Gilbert
• Massachusetts General Hospital — Boston
• Dana Farber Cancer Institute — Boston
• University of Pittsburgh Medical Center — Pittsburgh
• Mary Crowley Cancer Research — Dallas
• Virginia Cancer Specialists — Fairfax

Australia · 3 centers

• Southern Oncology — Bedford Park
• Peninsula & South Eastern Haematology and Oncology Group — Frankston
• The Alfred — Melbourne

Identifiers

NCT: NCT04370587 · CTIV1708

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗